昂飞公司确定三名受助者进行肿瘤特性分析

  今天美国昂飞公司(Affymetrix)宣布它们已经选定了三名受助者用于进行美国的肿瘤分析奖励项目。
  该项目发起于2014年，用于支持转化癌症医学领域研究者进行寻找并确定新型具有诊断、预测及治疗性的生物标志物，这获将满足当前临床的部分需求。
  为了使得这项计划变得合格就必须使用基于多组学、多系统的方法来对多个分子及细胞水平的数据进行分析确定未来可以用于临床的强效癌症生物标志物；而受助者将获得来自昂飞的产品用于调查和并且至少对两种不同的分析物进行结合性分析，这就包括来自于30份肿瘤样本的DNA、RNA及蛋白质。
  2015年的受助者包括来自霍普金斯大学医学院的Tamara Lotan，对其的研究计划名为“从无痛前列腺癌中区分恶性癌症的分子指纹图谱”；来自美国西北大学的Gayle Woloschak，研究计划名为“鉴别放疗和化疗后和宫颈癌复发相关的生物标志物”；来自哥伦比亚大学的Antonia Sepulveda，研究计划名为“胰腺癌早期诊断中基因组基因表达改变的结合分析”。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Affymetrix Names Tumor Profiling Grant Recipients

Affymetrix today announced three recipients of its US tumor profiling grant program.

First launched in 2014, the program is designed to support translational cancer researchers in the discovery and validation of novel diagnostic, prognostic, and therapeutic biomarkers that may address an unmet clinical need.

Qualifying grant projects must use a multi-omics, systems-based approach that analyzes data from multiple molecular and cellular levels to identify robust cancer biomarkers for future application in the clinic. The recipients are awarded with products from Affymetrix to investigate and combine analysis of at least two different analytes — DNA, RNA, or protein — across 30 tumor samples.

The 2015 grant recipients include Tamara Lotan from Johns Hopkins School of Medicine, for a project entitled "Molecular profiling to distinguish aggressive from indolent prostate cancer;" Gayle Woloschak of Northwestern University, for "Determination of biomarkers associated with cervical cancer relapse following radiation or chemo-radiation therapy;" and Antonia Sepulveda of Columbia University, for "Integrated analysis of genomic gene expression alterations for early detection in pancreatic cancer."